Kuehnle I, Huls M H, Liu Z, Semmelmann M, Krance R A, Brenner M K, Rooney C M, Heslop H E
Center for Cell and Gene Therapy and Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA.
Blood. 2000 Feb 15;95(4):1502-5.
After bone marrow transplantation (BMT) using T-cell-depleted marrow from an unrelated donor or HLA-mismatched related donor, the risk of developing lymphoproliferative disease associated with the Epstein-Barr virus (EBV) ranges from 1% to 25%. We have shown that administration of donor-derived EBV-specific cytotoxic T lymphocytes (CTL) is effective prophylaxis and treatment for this complication, and we routinely generate CTL for high-risk patients. However, EBV lymphoma can occur in recipients of matched-sibling transplants for whom CTL are unavailable or in patients for whom CTL administration is contraindicated. We report on 3 such patients, who were successfully and safely treated with rituximab, a CD20 monoclonal antibody. The patients remain disease free 7, 8, and 9 months, respectively, after therapy. We conclude that CD20 antibody may be a useful alternative treatment strategy in patients with EBV lymphoma after BMT. (Blood. 2000;95:1502-1505)
使用来自无关供体或HLA不匹配相关供体的去除T细胞的骨髓进行骨髓移植（BMT）后，发生与爱泼斯坦-巴尔病毒（EBV）相关的淋巴增殖性疾病的风险为1%至25%。我们已经表明，给予供体来源的EBV特异性细胞毒性T淋巴细胞（CTL）是预防和治疗这种并发症的有效方法，并且我们常规为高危患者产生CTL。然而，EBV淋巴瘤可发生在无法获得CTL的匹配同胞移植受者中，或发生在禁忌给予CTL的患者中。我们报告了3例这样的患者，他们用CD20单克隆抗体利妥昔单抗成功且安全地进行了治疗。治疗后，患者分别在7、8和9个月时保持无病状态。我们得出结论，CD20抗体可能是BMT后EBV淋巴瘤患者一种有用的替代治疗策略。（《血液》。2000年；95:1502 - 1505）
